Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person16
LeonaBio, Inc.
Company
Leonardo DRS, Inc.
Company
iBio, Inc.
Company
IN8BIO, INC.
Company
Lemonade, Inc.
Company
LENSAR, Inc.
Company
Q32 Bio Inc.
Company
GRI Bio, Inc.
Company
LiveOne, Inc.
Company
NIO Inc.
Company
KALA BIO, Inc.
Company
Inmune Bio, Inc.
Company
Leslie's, Inc.
Company
TRex Bio, Inc.
Company
TELA Bio, Inc.
Company
Instil Bio, Inc.
Company
Primary record10
LeonaBio, Inc. filed SCHEDULE 13D/A
, as amended, is attached as Exhibit 7 hereto. 250 E. Broad Street, Suite 250, Columbus, OH 43215 The principal business of Sermonix is pharmaceutical intellectual property licensing and clinical development. The princip
LeonaBio, Inc. filed 4
SEC form 4 filed by LeonaBio, Inc. (CIK 1620463) on 2026-10-28.
LeonaBio, Inc. filed 4
SEC form 4 filed by LeonaBio, Inc. (CIK 1620463) on 2026-10-26.
LeonaBio, Inc. filed SCHEDULE 13D/A
0001193125-26-431897.txt : 20261026 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001193125-21-032496 0001224962 XXXXXXXX LIVE 9 Common Stock, $0.0001 par value 10/26/2026 false 0001620463 04746L203 LeonaBio, In
LeonaBio, Inc. filed 8-K
Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the Company ) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the Series A Common Warrants ). T
LeonaBio, Inc. filed SCHEDULE 13D
, as amended, is attached as Exhibit 7 hereto. 250 E. Broad St., Suite 250 Columbus, OH 43215 The principal business of Sermonix Pharmaceuticals, Inc. is pharmaceutical intellectual property licensing and clinical develo
LeonaBio, Inc. filed 8-K
Item 8.01 Other Events. On August 26, 2026, LeonaBio, Inc. (the Company ) announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with
LeonaBio, Inc. filed SCHEDULE 13D/A
0001193125-26-365096.txt : 20260825 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001193125-21-032496 0001224962 XXXXXXXX LIVE 8 Common Stock, $0.0001 par value 08/22/2026 false 0001620463 04746L203 LeonaBio, In
LeonaBio, Inc. filed SCHEDULE 13G/A
0001636587-26-000069.txt : 20260820 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001636587-25-000065 0001766853 XXXXXXXX LIVE 2 Common Stock, $0.0001 Par Value 08/18/2026 0001620463 LeonaBio, Inc. 04746L203 187
LeonaBio, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 14, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press